论文部分内容阅读
目的对不同剂量厄贝沙坦治疗糖尿病肾病(DN)患者疗效进行比较。方法将56例糖尿病肾病患者随机分为治疗组(300mg/d)和对照组(150mg/d)各28例,观察治疗前及治疗3个月后血压、血肌苷(Scr)、血尿素氮(BUN)、血清钾(K)及尿微量白蛋白的变化。结果两组患者治疗后血压都有降低,但差异无统计学意义(P>0.05),尿白蛋白治疗后均显著下降(P<0.01),治疗组下降更为显著(P<0.05)。结论大剂量厄贝沙坦(300mg/d)降尿白蛋白优于小剂量厄贝沙坦(150mg/d),对DN患者有独立于血压之外的肾脏保护作用,安全性好。
Objective To compare the curative effects of different doses of irbesartan on patients with diabetic nephropathy (DN). Methods Fifty - six patients with diabetic nephropathy were randomly divided into treatment group (300mg / d) and control group (150mg / d) for 28 cases. Blood pressure, serum creatinine (Scr), blood urea nitrogen (BUN), serum potassium (K) and urinary microalbumin. Results After treatment, the blood pressure was decreased in both groups, but the difference was not statistically significant (P> 0.05). The urine albumin decreased significantly after treatment (P <0.01), and the treatment group decreased more significantly (P <0.05). Conclusions High-dose irbesartan (300 mg / d) is superior to low-dose irbesartan (150 mg / d) in reducing kidney damage in patients with DN, which is independent of blood pressure and has good safety.